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Summary
Background: Chronic obstructive pulmonary disease (COPD) frequently coexists in patients
with chronic heart failure (CHF) and is a key factor for beta blocker underprescription and
underdosing. This study compared effects of bisoprolol and carvedilol in patients with both
conditions.
Methods: This was a randomized open-label study, of bisoprolol and carvedilol during
initiation and uptitration to target or maximal tolerated dose. Pulmonary function testing,
12-lead electrocardiogram, and N-terminal pro brain natriuretic peptide were measured
at baseline and follow-up.
Results: We randomized 63 elderly patients (73±9 years, 81% men, left ventricular
ejection fraction 33±7%) with mild to moderate CHF (54% New York Heart Assocation
class II) and moderate to severe COPD (76% Global initiative for chronic Obstructive Lung
Disease stage 2). Target dose was tolerated by 31 (49%) patients and 19 (30%) patients
experienced adverse events during follow-up (19% bisoprolol, 42% carvedilol, p = 0.045).
Study medication had to be withdrawn in 8 (13%) patients (bisoprolol: 2 due to hypotension,
1 due to bradycardia; carvedilol: 2 due to hypotension and 1 due to wheezing, dyspnoea,
and oedema, respectively). Forced expiratory volume in 1st second signiﬁcantly increased
in bisoprolol (1561±414ml to 1698±519ml, p = 0.046) but not carvedilol (1704±484 to
1734±548, p = 0.44) group. Both agents reduced heart rate (bisoprolol: 75±14 to 68±10,
p = 0.007; carvedilol 78±14 to 72±12, p = 0.016) and had no effect on N-terminal pro brain
natriuretic peptide.
Conclusions: Beta blockers frequently caused adverse events, and thus 49% of patients
could tolerate the target dose. Bisoprolol induced demonstrable improvement in
pulmonary function and caused less adverse events.
© 2011 Elsevier Ltd. All rights reserved.
Introduction
Co-morbidities have recently received increasing research
and clinical interest in patients with chronic heart
failure (CHF).1,2 Landmark randomized controlled trials
established beta blockers as mainstay therapy in CHF with
reduced left ventricular ejection fraction.3 Translation to
clinical practice, however, remains suboptimal due to many
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reasons. Chronic obstructive pulmonary disease (COPD) is
present in about one third of CHF patients and is among
key factors for underprescription and underdosing of beta
blockers.4–6 Although concern about precipitating respiratory
deterioration exists, clinical signiﬁcance remains poorly
determined.
Among the pharmacologically distinct agents carvedilol,
bisoprolol, metoprolol, and nebivolol, some differences in
side effect proﬁle due to cardioselectivity exist.7 Most large-
scale CHF trials excluded patients with COPD,8 thus safety
and efﬁcacy data is largely derived from observational
studies which suggest that beta blockers are beneﬁcial.9,10
Only few studies evaluated pulmonary function in patients
with CHF and even less compared effects of different beta
blockers in coexisting COPD.11–14 It was shown that bisoprolol
causes reduction in pulmonary function test parameters but
without change in symptoms and quality of life.15 Further
studies suggest differences in pulmonary effects between
selective and non-selective beta blockers9,12 but the results
are not conclusive.
No study prospectively evaluated effects of selective and
non-selective beta blockers, titrated to target or maximal
tolerated dose in patients with coexisting CHF and COPD. In
this randomized study, pulmonary and cardiovascular effects
of bisoprolol and carvedilol were compared in beta blocker
naïve patients.
Methods
Study design and patients
This randomized open-label study was conducted at the
Department of Internal Medicine, General Hospital Murska
Sobota, and at the Division of Cardiology, University Clinic
or Respiratory and Allergic Diseases Golnik, both in Slovenia.
Eligible patients with established CHF (LVEF 40%) and
COPD according to guidelines3,16 were included if clinically
stable and beta blocker naïve. Principal exclusion criteria
were cardiovascular contraindications to beta blocker
therapy (atrioventricular block greater than 1st degree
without a pacemaker, bradycardia <60 beats per minute,
hypotension deﬁned as systolic blood pressure <100mmHg,
symptomatic peripheral obstructive artery disease at rest,
acute heart failure), and those with history of asthma. After
baseline investigations, patients were randomly assigned
to bisoprolol and carvedilol in a 1:1 fashion. Beta blocker
was uptitrated by doubling the dose every 2–4 weeks and
patients were titrated to target or maximal tolerated dose,
followed by a 4–6 weeks maintenance phase. Study protocol
was approved by the national Ethics Committee; study
subjects received written and verbal information about the
study and signed informed consent form prior to any study
related procedure.
Investigations and data collection
Baseline investigations prior to beta blocker initiation
and after the maintenance phase included demographic
characteristics, patient history, physical examination, 12-
lead electrocardiogram, laboratory investigations, 6-minute
walk test, echocardiography, and pulmonary function
testing. Echocardiography was performed according to
Heart Failure Association guidelines.3 At titration visits,
patient history, physical examination, and 12-lead electro-
cardiogram were performed routinely. At follow-up visit,
pulmonary function testing and laboratory investigations
were added. Laboratory investigations included NT-pro brain
natriuretic peptide (NT-proBNP), haemoglobin, creatinine,
and potassium. Spirometry was performed in accordance
with guidelines16 and following parameters were measured:
the forced expiratory volume in 1st second (FEV1), vital
capacity (VC), and peak expiratory ﬂow (PEF).
Statistical analysis
Continuous variables are presented as mean value±standard
deviation or as median (interquartile range). Categorical
variables are presented as absolute number and percent-
ages. Primary outcome measure was FEV1, and secondary
outcome measures were other measures of pulmonary
function, heart rate form resting 12-lead electrocardiogram,
and NT-proBNP. To evaluate the differences between
patients treated with bisoprolol and carvedilol, the
Student’s t-test, chi-square test, and Mann Whitney U test
were used as appropriate. Baseline and follow-up results
were compared with paired t-test. Statistical analyses were
performed on SPSS for Windows version 16.0 (SPSS Inc.,
Chicago, IL) and Prism 5 for Windows (GraphPad Software,
Inc., San Diego, CA).
Results
Patient characteristics
We included 63 elderly patients (73±9 years), who were
predominantly male (81% men). Important co morbidities
included ischemic heart disease and arterial hypertension,
patients had average left ventricular fraction of 33±7%, and
were in NYHA class II (54%) or III (46%). According to GOLD,
pulmonary function was moderately (76%) or severely (24%)
impaired with a FEV1 of 1631±452ml (60±13% of predicted).
At baseline, there were no signiﬁcant differences between
patients randomized to bisoprolol (N = 32) and carvedilol
(N = 31) – Table 1.
Pulmonary and cardiovascular outcomes
Table 2 and Figure 1 present pulmonary function parameters
at baseline and at follow-up. FEV1 signiﬁcantly increased
in the bisoprolol (1561±414ml to 1698±519ml, p = 0.046)
but not in the carvedilol (1704±484 to 1734±548, p = 0.44)
group – Table 2 and Fig. 1. FEV1 increased in 66% and 48% of
patients receiving bisoprolol and carvedilol, and 7 patients
(3 bisoprolol, 4 carvedilol) had at least 12% reduction of
FEV1. Differences in other pulmonary function parameters
were not signiﬁcant (Table 2). Bisoprolol (75±14 to 68±10
beats/minute, p = 0.007) and carvedilol (78±14 to 72±12
beats/minute, p = 0.016) signiﬁcantly reduced the heart
rate but the difference between agents was not signiﬁcant
(Fig. 2).
No signiﬁcant difference from baseline to follow-up and
between the agents was observed for systolic and diastolic
blood pressure. An increase in NT-proBNP concentration
was detected in 52% and 63% of patients receiving
bisoprolol (1210±1256 to 1259±1463 pg/mL, p = 0.86) and
carvedilol (1340±1296 to 1531±1507 pg/mL, p = 0.24) but
the differences were not signiﬁcant (Fig. 3).
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Table 1
Patient baseline characteristics
Bisoprolol (N = 32) Carvedilol (N = 31) p
Age [years] 72±8 73±9 0.77
Men 25 (78%) 26 (84%) 0.56
Body mass index [kg/m2] 27.8±3.9 26.8±5.4 0.38
Heart rate [beats/min] 75±15 78±13 0.66
Systolic blood pressure [mmHg] 134±19 134±20 0.43
Diastolic blood pressure [mmHg] 80±12 78±11 0.61
6-minute walk distance [m] 303±71 302±110 0.26
New York Heart Association class II/III 17/15 (53%/47%) 17/14 (55%/45%) 0.89
Left ventricular ejection fraction [%] 33±7 32±8 0.27
Global Obstructive Lung Disease stage II/III 24/8 (75%/25%) 24/7 (77%/23%) 0.82
Forced expiratory volume in 1st second [ml] 1561±414 1704±484 0.20
Vital capacity [ml] 2630±715 2819±608 0.12
Current/Ex smoker 26 (81%) 26 (84%) 0.78
Ischemic heart disease 23 (72%) 20 (65%) 0.53
Arterial hypertension 26 (81%) 23 (74%) 0.50
Diabetes nellitus 10 (31%) 11 (35%) 0.72
Atrial ﬁbrillation 7 (22%) 5 (16%) 0.56
Haemoglobin [g/L] 141±11 137±16 0.24
Creatinine [mmol/L] 114±36 118±33 0.80
Potassium [mmol/L] 4.5±0.5 4.5±0.4 0.91
Cardiovascular therapy
Angiotensin converting enzyme inhibitors 28 (88%) 26 (84%) 0.68
Loop diuretics 22 (69%) 18 (58%) 0.38
Spironolactone 13 (41%) 9 (29%) 0.33
Pulmonary inhalative therapy
Short acting beta agonist 29 (91%) 29 (94%) 0.67
Long acting beta agonist 20 (62%) 18 (58%) 0.72
Inhaled corticosteroids 19 (59%) 18 (58%) 0.92
Anticholinergic agent 21 (66%) 19 (61%) 0.72
Data are presented as mean±standard deviation, or number (percentage).
Table 2
Respiratory function outcomes
Bisoprolol (N = 32) Carvedilol (N = 31) p
Forced expiratory volume in 1st second [%]
Baseline 58±12 62±14 0.36
Follow-up 65±16 64±18 0.74
p 0.01 0.29
Vital capacity [%]
Baseline 75±16 78±14 0.59
Follow-up 81±19 77±16 0.28
p 0.13 0.47
Peak expiratory ﬂow [ml/s]
Baseline 438±179 430±178 0.72
Follow-up 465±195 454±220 0.54
p 0.24 0.15
Data are presented as mean±standard deviation.
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Fig. 1. Forced expiratory volume in 1st second at baseline and at
follow-up.
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Fig. 2. Heart rate at baseline and at follow-up.
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Fig. 3. N-terminal brain natriuretic peptide at baseline and at
follow-up.
Titration and adverse events
The mean daily dose of bisoprolol and carvedilol at follow-
up was 6.4 and 47mg, respectively. Target dose was
tolerated by 49% of patients (56% bisoprolol, 42% carvedilol).
During follow-up, 24 adverse events in 19 (30%) patients
were reported: 6 (19%) on bisoprolol and 13 (42%) on
carvedilol (p = 0.045). Most of them were mild and transient
and no measures were needed. Study medication had to
be withdrawn in 8 (13%) patients (bisoprolol: 2 due to
hypotension, 1 due to bradycardia; carvedilol: 2 due to
hypotension and 1 due to wheezing, dyspnoea, and oedema,
respectively). During titration, study drug dose had to be
reduced in 10 (16%) patients and titration was temporarily
interrupted in 19 (30%) patients.
Discussion
Initiation and uptitration of beta blockers in patients with
coexisting CHF and COPD to target or maximal tolerated
dose was possible in 87% of patients and 49% reached target
dose. Adverse events and study medication withdrawal were
more frequent in carvedilol group. Cardiovascular effects
were similar; however, bisoprolol had more favorable effects
on pulmonary function and caused less pulmonary adverse
events.
Airway obstruction during treatment with beta blockers is
mediated through interference with b2-receptor mediated
bronchodilatation7 and remains a valid concern. Due to
pharmacological properties, such events are more frequent
but not limited to non-selective agents (e.g. carvedilol),
which are up to 120 times less selective for b1- than
b2-receptor than selective agents (e.g. bisoprolol).17 Indeed,
in patients with CHF and moderate to severe COPD,
bisoprolol signiﬁcantly reduced FEV1 when compared to
placebo.15 However, no symptom deterioration, quality of
life reduction, or drug discontinuation was needed, which
again suggests individual evaluation of side effects. In
a recent trial that included 35 patients with coexisting
COPD and CHF, carvedilol caused signiﬁcant FEV1 reduction
which was well tolerated.11 Bisoprolol, on the other hand,
induced FEV1 increase and the difference between agents
was also signiﬁcant (mean difference 150ml, 95%CI +40 to
+260ml, p < 0.01). Long acting beta agonists like salbutamol,
are COPD mainstay therapy, and were prescribed to 60%
of our patient cohort. In this context, study by Agostoni
et al. is relevant.18 Response to salbutamol was tested
in 53 CHF patients on background beta blocker therapy
and it was signiﬁcantly higher in patients on bisoprolol
when compared to carvedilol (p = 0.04). We share the
observations with previous studies about pulmonary test
ﬁndings and pulmonary adverse events. Bisoprolol increased
FEV1 whereas carvedilol induced no signiﬁcant changes
but the clinical relevance should be assessed individually.
In many cases, the beneﬁts could outweight risks and
patients should not be withheld this life saving therapy.19
Even in reversible airway obstruction, this could be the
case: according to Kotlyar et al.,20 50% of asthma patients
tolerated non-selective beta blockade with carvedilol.
Coexisting COPD in patients with CHF has important
therapeutic and prognostic implications. Although not a
valid contraindication, clinicians frequently withhold beta
blockers in patients with COPD due to concern of pulmonary
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and other deteriorations. Beta blockers induce worsening
of clinical symptoms and signs in most patients but this
frequently is mild and transient event. Natriuretic peptides
seem to follow the clinical course of transient increase
in serum concentration,21 a pattern not too different as
observed with our baseline and follow-up measurement.
Guideline translation in frail and high-risk patients may
therefore be prolonged and more caution should be
taken in titration decisions. Crucial step seems to be
therapy initiation which is less likely to be performed
by inexperienced personnel. Once started on the beta
blocker, titration intervals and daily dose can be adjusted
to the patient. Due to the system capacity, which outside
of specialized settings like heart failure clinics may not
allow for two week titration visits,22 titration interval is
prolonged which may in fact be beneﬁcial for the patients.
The SATELLITE survey23 tried to resemble clinical practice:
531 physicians (61% cardiologist, 38% internists) started
carvedilol in 3721 CHF patients (mean age 65 years, 60%
men), and up-titration decisions were left to the attending
physician. At 6 months the mean daily dose of carvedilol was
31±11mg whereas 50mg and 25mg were prescribed to 26%
and 35%, respectively. During study period of 6 months, 11%
reported adverse events but withdrawal or substitution for
another agent was needed only in 1.4% of patients.
Limitations
This study has to be interpreted in view of some limitations.
It was an open label study in a relatively small number
of patients which however is not different from previous
studies.6 We also cannot entirely exclude contribution of left
ventricular dysfunction and CHF deterioration to pulmonary
function results. This however may be unlikely in view of
few adverse events due to heart failure deterioration and
no apparent differences in NT-proBNP.
Conclusions and clinical implications
Patients with CHF due to left ventricular systolic dysfunction
and coexistent COPD should not be withheld life saving
therapy with beta blockers. Our study, along with previous
reports, demonstrates that these patients are able to
tolerate beta blockers. In clinical practice, a slower
titration with more frequent follow-up visits and additional
considerations about beta blocking agent selection is
warranted. In this particular patient subgroup, pulmonary
function testing and, in some cases, referral to pneumologist
may be necessary to individually tailor guideline suggested
management.
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